MA
SLXN

Montag & Associates’s Silexion Therapeutics SLXN Stock Holding History

Montag & Associates’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.84K Hold
300
– – ﹤0.01% 810
2025
Q4 		$5.76K Hold
300
– – ﹤0.01% 809
2025
Q3 		$10.2K Buy
+300
New +$24.9K ﹤0.01% 765

Other funds holding SLXN

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Montag & Associates's SLXN Position: Q1 2026 in Review

Montag & Associates held its Silexion Therapeutics (SLXN) position steady in Q1 2026 at 300 shares worth $3.84K. The position accounts for ﹤0.01% of the portfolio, ranked #810.

Montag & Associates first reported a position in SLXN in Q3 2025 and has held it in 3 quarters since. The position peaked at $10.2K in Q3 2025. 7 funds tracked by Wall St. Rank hold SLXN as of Q1 2026.

  • Montag & Associates held 300 shares of Silexion Therapeutics worth $3.84K as of Q1 2026.
  • Montag & Associates left its Silexion Therapeutics share count unchanged in Q1 2026.
  • Silexion Therapeutics made up ﹤0.01% of Montag & Associates's portfolio in Q1 2026, its #810 holding.
  • Montag & Associates first reported a position in Silexion Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Montag & Associates's Silexion Therapeutics position peaked at $10.2K in Q3 2025.
  • 7 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q1 2026.

Based on Montag & Associates's 13F filing for Q1 2026, filed 29 Apr 2026.